Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital

The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery

Research output: Contribution to journalJournal articleResearchpeer-review

  1. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dangers of hyperoxia

    Research output: Contribution to journalReviewResearchpeer-review

  3. Letter the editor: serious methodological concerns about a recently published meta-analysis on oxygen therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prediction of severe adverse event from vital signs for post-operative patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Andre Lamy
  • Wesley Tong
  • Rajibul Mian
  • Jessica Vincent
  • Wojciech Szczeklik
  • Bruce M Biccard
  • Emmanuelle Duceppe
  • Maria Graza Franzosi
  • Sadeesh K Srinathan
  • Christian S Meyhoff
  • Joel Parlow
  • Denis Xavier
  • P J Devereaux
View graph of relations

BACKGROUND: The Management of Myocardial Injury after Non-Cardiac Surgery (MANAGE) trial demonstrated that dabigatran 110 mg twice daily was more effective than placebo in preventing the primary composite outcome of vascular mortality, non-fatal myocardial infarction, non-hemorrhagic stroke, peripheral arterial thrombosis, amputation and symptomatic venous thromboembolism in patients with myocardial injury after non-cardiac surgery (MINS). The cost implications of dabigatran for this population are unknown but are important given the significant clinical implications.

METHODS: Hospitalized events, procedures, and study and non-study medications were documented. We applied Canadian unit costs to healthcare resources consumed for all patients in the trial, and calculated the average cost per patient in Canadian dollars for the duration of the study (median follow-up of 16 months). A sensitivity analysis was performed using only Canadian patients, and subgroup analyses were also conducted.

RESULTS: The total study cost for the dabigatran group was $9985 per patient, compared with $10,082 for placebo, a difference of - $97 (95% confidence interval [CI] - $2128 to $3672). Savings arising from fewer clinical events and procedures in the dabigatran 110 mg twice-daily group were enough to offset the cost of the study drug. In Canadian patients, the difference was $250 (95% CI -$2848 to $4840). Both differences were considered cost neutral. Dabigatran 110 mg twice daily was cost saving or cost neutral in many subgroups that were considered.

CONCLUSION: Dabigatran 110 mg twice daily was cost neutral for patients in the MANAGE trial. Our cost findings support the use of dabigatran 110 mg twice daily in patients with MINS.

TRIAL REGISTRATION: identifier number NCT01661101.

Original languageEnglish
JournalAmerican Journal of Cardiovascular Drugs
Issue number1
Pages (from-to)83-91
Publication statusPublished - 2022

Bibliographical note

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

ID: 68495987